Psoriasis is a chronic disease that can affect many areas of the body. The use of topical corticosteroids (TCS) is a common treatment, although long-term safety of TCS remains a concern.
A recent article in Dermatology Times cites a Journal of Drugs in Dermatology study which examines how Topical Halobetsol Propionate 0.01% lotion appears to “safely and quickly improve lower-extremity psoriatic lesions,” over typical TCS treatments.
“A post hoc analysis of data from phase 3 studies investigating the e fficacy of halobetasol propionate 0.01% lotion for treating moderate-to-severe plaque psoriasis showed that the topical corticosteroid was associated with rapid improvement, and findings should help dermatologists with treatment decisions for patients with disease involving leg lesions, said Neal Bhatia, M.D., director of clinical dermatology at Therapeutics Clinical Research, San Diego, and the lead author of the paper.”
At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).
View Article Now
